kt 6149 has been researched along with Bone Marrow Diseases in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Dumortier, A; Evene, E; Joossens, E; Koier, I; Provè, A; Schrijvers, D | 1 |
Ashizawa, T; Gomi, K; Hirata, T; Okabe, M | 1 |
1 trial(s) available for kt 6149 and Bone Marrow Diseases
Article | Year |
---|---|
Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biotransformation; Bone Marrow Diseases; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Half-Life; Humans; Liver Neoplasms; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Unknown Primary; Salvage Therapy | 1995 |
1 other study(ies) available for kt 6149 and Bone Marrow Diseases
Article | Year |
---|---|
Reduced bone marrow toxicity of KW-2149, a mitomycin C derivative, in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blood Cell Count; Bone Marrow Diseases; Colony-Forming Units Assay; Female; Hematopoietic Stem Cells; Lung Diseases; Male; Megakaryocytes; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mitomycin; Mitomycins; Organ Size; Spleen; Tumor Cells, Cultured | 1993 |